Prof Neeraj Agarwal speaks to ecancer about the SWOG S1216 trial. It investigated ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC.

Initially, he talks about the rationale of the study. Dr Agarwal then describes the methodology and key results of this study. This trial sets a new landmark for survival estimates when patients with mHSPC have access to multiple approved subsequent life-prolonging therapies. Prof Agarwal states that the median OS of 70 months in the control arm (standard ADT) was higher than that reported in contemporary phase 3 trials in this setting, and 16 months higher than originally estimated. In the end, he discussed the impact of these results on the future treatment of this type of prostate cancer.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

0 Comments

Up next

Autoplay

Phenytoin (Dilantin): Anticonvulsant Drug for Tonic-clonic or Partial Seizures in Epilepsy Patients

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC

Up next

Language